Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -63.61% is 207% below its 5-year average of -20.71%, near the low end of its 5-year range (-63.61%–13.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 45.84% below its 12-month average of -43.62%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -63.61%.
RETURN ON INVESTED CAPITAL (ROIC)
-63.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-43.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-16.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-20.71%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-45.84%
CURRENT VS 3Y AVG
-297.55%
CURRENT VS 5Y AVG
-207.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
-78.38%
vs the sector median at left
Entrada Therapeutics, Inc.
Market Cap
$210.41M
Return on Invested Capital (ROIC)
-63.61%
TTM Avg
-43.62%
3Y Avg
-16.00%
5Y Avg
-20.71%
Market Cap
$209.91M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$210.98M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-76.09%
3Y Avg
-51.87%
5Y Avg
-42.00%
Market Cap
$208.31M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Return on Invested Capital (ROIC)
14.99%
TTM Avg
15.04%
3Y Avg
13.17%
5Y Avg
12.12%
Market Cap
$214.24M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
15.21%
3Y Avg
-9.34%
5Y Avg
-32.56%
Market Cap
$214.46M
Return on Invested Capital (ROIC)
-40.18%
TTM Avg
-34.28%
3Y Avg
-58.87%
5Y Avg
-58.87%
Market Cap
$205.80M
Return on Invested Capital (ROIC)
-47.05%
TTM Avg
-105.31%
3Y Avg
-79.09%
5Y Avg
-78.87%
Market Cap
$215.07M
Return on Invested Capital (ROIC)
19.13%
TTM Avg
15.37%
3Y Avg
31.31%
5Y Avg
44.42%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.41M | -63.61% | -43.62% | -16.00% | -20.71% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 26.14% | 3.79% | -12.27% | -17.37% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -70.80% | -76.09% | -51.87% | -42.00% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 14.99% | 15.04% | 13.17% | 12.12% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 8.84% | 15.21% | -9.34% | -32.56% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -40.18% | -34.28% | -58.87% | -58.87% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -47.05% | -105.31% | -79.09% | -78.87% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 19.13% | 15.37% | 31.31% | 44.42% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -43.74% | -105.81% | -81.36% | -65.49% |
ROIC
-63.6%
ROE
-71.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -63.61% |
| 2026-03-31 | -56.40% |
| 2025-12-31 | -44.74% |
| 2025-09-30 | -30.91% |
| 2025-06-30 | -22.42% |
| 2025-03-31 | 0.88% |
| 2024-12-31 | 9.53% |
| 2024-09-30 | 8.58% |
| 2024-06-30 | 13.55% |
| 2024-03-31 | 3.87% |
| 2023-12-31 | -0.56% |
| 2023-09-30 | -5.79% |
| 2023-06-30 | -20.00% |
| 2023-03-31 | -24.66% |
| 2022-12-31 | -42.27% |
| 2022-09-30 | -35.64% |
| 2022-06-30 | -28.27% |
| 2022-03-31 | -21.54% |
| 2021-12-31 | -17.09% |
| 2021-09-30 | -32.99% |
| 2021-06-30 | -24.41% |
| 2020-12-31 | -66.39% |
